BNP Paribas Financial Markets Purchases 39,919 Shares of argenex SE $ARGX

BNP Paribas Financial Markets grew its holdings in shares of argenex SE (NASDAQ:ARGX) by 59.8% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 106,714 shares of the company’s stock after purchasing an additional 39,919 shares during the quarter. BNP Paribas Financial Markets’ holdings in argenex were worth $78,708,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. AQR Capital Management LLC raised its position in shares of argenex by 32.1% in the first quarter. AQR Capital Management LLC now owns 502 shares of the company’s stock valued at $297,000 after purchasing an additional 122 shares during the period. NewEdge Advisors LLC boosted its holdings in argenex by 5,962.5% in the 1st quarter. NewEdge Advisors LLC now owns 1,455 shares of the company’s stock worth $862,000 after buying an additional 1,431 shares during the period. Focus Partners Wealth boosted its holdings in argenex by 22.3% in the 1st quarter. Focus Partners Wealth now owns 400 shares of the company’s stock worth $237,000 after buying an additional 73 shares during the period. Geneos Wealth Management Inc. grew its stake in argenex by 550.0% in the 1st quarter. Geneos Wealth Management Inc. now owns 117 shares of the company’s stock valued at $69,000 after buying an additional 99 shares in the last quarter. Finally, Vestmark Advisory Solutions Inc. bought a new stake in argenex during the 2nd quarter valued at $367,000. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Stock Performance

argenex stock opened at $708.85 on Friday. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The stock has a market cap of $43.86 billion, a P/E ratio of 36.31, a PEG ratio of 1.20 and a beta of 0.38. The firm’s fifty day moving average price is $806.79 and its 200-day moving average price is $815.81.

argenex (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, February 26th. The company reported $8.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.05 by $1.97. argenex had a return on equity of 38.51% and a net margin of 30.42%.The company had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. Sell-side analysts predict that argenex SE will post 3.13 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. Wall Street Zen downgraded argenex from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Wolfe Research reiterated a “peer perform” rating on shares of argenex in a research note on Monday, November 24th. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Robert W. Baird raised their target price on argenex from $858.00 to $867.00 and gave the stock a “neutral” rating in a research note on Friday, February 27th. Finally, HC Wainwright lifted their target price on argenex from $915.00 to $940.00 and gave the company a “buy” rating in a report on Friday, February 27th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $999.22.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.